Foren & Soziale Netzwerke zur HIMS & HERS Aktie

 

Kursziel: 27.8048 €

I like HIMS and OSCR A LOT in this market and environment right now. :) So, getting HIMS at $38 seems like a gift. JUST closed .80 gain on a put sale. So cost basis would be a tad lower than $37 if I get put shares...

HIMS is incredibly profitable and also a highly shorted stock (33%). It might tap support here, but if not just below the trend line seems like a nice entry. Good luck!

THIS HAS BEEN such a fun stock to trade. BIG DOWN DAY. This put sale is before earnings. AMAZING premiums. Puts the cost basis at $44. GORGEOUS

- NYSE:HIMS is quite overvalued. There's no moat to a business model. - They got a good branding that's all. There are 10-15 other startups selling the same things under different umbrella. - They even stole NYSE:NVO flagship weight loss drugs. These cheap alternatives will risk lives of people and will open plethora of lawsuits. - Growth is slowing down to low 20s which calls for correction in the multiple. - Anyone paying more than 20x will likely suffer from massive losses within an year timeframe. - Fundamentally, Year | 2025 | 2026 | 2027 | 2028 EPS | 0.57 | 0.79 | 1.05 | 1.40 EPS% | 5.76% | 38.31% | 32.59% | 33.25% Giving benefit of doubt and being generous, 30x multiple as a base case. Fair stock value: Year | 2025 | 2026 | 2027 | 2028 Price | $17 | $23 | $31 | $42 - We should visit the $23-26 range somewhere in 2026

After retesting 3 times a fib fan resistence, i think it will break very strong this time and it will bounce much higher. Then, on weekly timeframe, it seems a nice cup and handle pattern, for this reason i hope it will go higher in medium-long term First target: 73 $ Second target: 90 $ Third target: 100 $

Kursziel: 506.0 €

NYSE:HIMS - Dip Buy Box Wins Again! Second time bouncing off our $40-45 support. Breaking out of downtrend with a strong bullish candle. Target $67 then $73 ?

HIMS — Metrics-Led Swing Plan (4H/12H) Your constraints New entry (early momentum): manage risk at 44. “Best safety” entry: 28. Targets: 50 → 54 → 59 → 70 → 85. Investment window: now → July 2026.--- State 1 — What the Metric Table is Saying (and how to act) Liquidity & Participation Float / Vol·Float: ~0.12× currently → drift/early trend regime. Rules: 51” (promote TP2 path). “Price < 44” (momentum plan invalidated). “Vol·Float ≥ 0.2× / 0.3×” (permission to widen targets). “Close < 48.2 VWAP then failure retest” (reduce risk).--- Disclaimer (read me) This is educational and based on what's visible on your screenshots/metrics. Markets change; confirm levels on your chart and adapt sizing to your own risk tolerance. No financial advice. Always use a hard stop and pre-define risk before entry.

HIMS is bouncing off an ascending support, as well as the 200day SMA. It has rising volume with MACD crossing above signal line. Entering 48c 19Dec2025

Hello I am the Cafe Trader. Today we're looking again at the hyped HIMS (Hims & Hers Health). This is a wide range, make sure you get good pricing if you add to the long term. Price is currently sitting right above Strong Buyers These buyers are holding, and the shorts may be exhausting having to cover soon. So I have provided a trade idea to finesse this action. . Green Scenario If buyers continue to hold this demand, I expect a push into the Bottom of Supply around 52. That's the first stop, and a strong reaction there would tell us whether Sellers are really active, or buyers are ready to push into the higher supply zones. The more aggressive case would be continuation all the way into the Extreme Supply area closer to 65–68. Long Term Aggressive: 44–45 (Strong Buyers, current zone) Extreme Value: 26 (Extreme Demand — if buyers completely lose control, this is where I'd expect institutions to step in). For now, HIMS looks bullish off this demand, but keep in mind that if we do lose this b

NYSE:HIMS LONG Swing Entry Plan Entry Zone 1: $46.10 – $46.50 → Open initial position targeting +8% from entry level. Entry Zone 2: $43.00 – $43.20 → If price dips further, average down with a second equal-sized entry. → New target becomes +8% from the average of Entry 1 and Entry 2. AD Zone : $37.80 – $38.50 → If reached, enter with double the initial size to lower the overall cost basis. → Profit target remains +8% from the new average across all three entries. Risk Management: Stop Loss: Risk is capped at 12% below the average entry price (calculated across all executed positions including the Edit Zone). Position Sizing Approach: Entry 1: 1x Entry 2: 1x AD Zone: 2x → Total exposure: 4x → Weighted average determines final TP and SL calculations. ______________________________________ Legal Disclaimer The information provided in this content is intended for educational and informational purposes only and does not constitute financial, investment, or legal advice or recommendations of any kind. T

8/5/25 :: VROCKSTAR :: NYSE:HIMS Shouldn't be green. - this is a trading man's game stock at the moment - but fundamentally, as a grow stock in a heady market, you can't be missing here and leaving wide gaps in guidance for hope - so yeah. i think seeing this thing go red to green is, frankly, surprising and makes me wonder how much liquidity needed to be grabbed on both sides of this thing - but i'd also believe we need to find a lower low (in the 40s before i'd consider owning it again). - gl to the bulls. i've only been in your camp - as you can see - on this chart over the last year/year and a half - but no way i'm owning this thing at this valuation. not a short. but a clear "avoid" at best in my book. be safe out there. don't let the blinders allow you to not manage size (e.g. trimming) is my friendly nudge V

NYSE:HIMS on the Daily Chart still with an ascending triangle - with resistance at $72-$70 - is still being respected with price touching the top trendline, with weakening volume, an evening star which is suggesting trend exhaustion from the rally from the 23rd June, succeeding the 30% drop from the head and shoulders pattern. On the 15m Chart, you can see a bull flag and pennant form which broke down with confluence from MACD and RSI showing downside pressure. forming a bear pennant. However, both indicators are now flashing bullish divergence — price action is printing lower lows, while RSI and MACD are printing higher lows. Premarket has broken above above the pennant, confirming the divergence.

NYSE:HIMS — daily chart shaping up nicely ? If it breaks above $53.39, next target could be $61.57 ? Clean setup with ascending support — let's see if volume steps in!

CLEAN breakout for NYSE:HIMS today. DP_ORB Indicator marked it at candle close outside of ORB Zone, with confirmation bias from a higher high, and volume. All take profits were hit! If you want the DP_ORB Indicator for FREE: https://www.tradingview.com/script/6Irjvn9A-DP-ORB-Entry-Exit-Indicator/

Kursziel: -

Kursziel: -

6/25/25 :: VROCKSTAR :: NYSE:HIMS How I'm trading this for size - i make a lot of moves, as you can tell. but you'll also notice i tend to find positions that i like as i validate the thesis... and go massive - NYSE:HIMS and NASDAQ:TSLA are two names that i'm not new to, but have been wrangling for some time given valuations really haven't been "cheap" per se. there's a good reason for that. - so $hims. i reset book last night, and now after seeing this thing to red on the day after opening to a squeeze nearly >5%... i'm back to wranging. i. want. to. own. this. it's scarce paper. a scarce CEO. scarce growth. and it's hitting right at the heart of the war on pharma, in it's own "novel" way that just makes me excited to root for the success. - valuation is not honestly, expensive - but communication and headlines will drive a lot of price action (as has been the case) now that NVO has unofficially announced that they're losing market share and, frankly, the stock is uninvestable and will ultimately u

6/23/25 :: VROCKSTAR :: NYSE:HIMS Time to re-accumulate - NYSE:NVO are playing dirty and this is a tell and low-key admission that NYSE:HIMS holds all the power - distribution is key... look at NASDAQ:META , NASDAQ:AAPL , $AMZN. he who holds the customer relationship makes the rules - there is no longer a major advantage in developing pharma, the majority of solutions can now roll off patents and/or be compounded *legally* - so what you're seeing here is cartel-like behavior from a slow motion train wreck NYSE:NVO - which i've liked the past - but ultimately the stock will lose to names like NYSE:HIMS (and other pharma too). - so will they get sued? who tf cares. we'll buy more - this is a rule of 40 winner, even if law suit is large, it won't affect the story and growth. and major kudos to Andrew (the rockstar CEO) that put out this tweet. this is a founder-leader you want to put your portfolio behind when the opportunities arise. i'll be looking for oppty in the coming days/weeks to own more o